HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Disorders of Excessive Somnolence (Hypersomnia)

Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
Also Known As:
Hypersomnia; Hypersomnolence; DOES (Disorders of Excessive Somnolence); Excessive Somnolence Disorders; Hypersomnia, Recurrent; Hypersomnolence Disorders; Hypersomnolence Disorders, Primary; Hypersomnolence Disorders, Secondary; Primary Hypersomnolence Disorders; Secondary Hypersomnolence Disorders; DOESs (Disorders of Excessive Somnolence); Daytime Sleepiness, Excessive; Daytime Sleepinesses; Daytime Somnolences; Excessive Daytime Sleepinesses; Excessive Somnolence Disorder; Hypersomnia Disorder, Primary; Hypersomnia Disorder, Secondary; Hypersomnias; Hypersomnolence Disorder; Hypersomnolence Disorder, Primary; Hypersomnolence Disorder, Secondary; Primary Hypersomnia Disorder; Primary Hypersomnolence Disorder; Recurrent Hypersomnia; Recurrent Hypersomnias; Secondary Hypersomnia Disorder; Secondary Hypersomnolence Disorder; Sleepiness, Daytime; Sleepiness, Excessive Daytime; Somnolence Disorder, Excessive; Somnolence, Daytime; Daytime Sleepiness; Daytime Somnolence; Excessive Daytime Sleepiness; Primary Hypersomnia Disorders; Secondary Hypersomnia Disorders
Networked: 2454 relevant articles (307 outcomes, 370 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Narcolepsy
2. Fatigue
3. Cataplexy
4. Obstructive Sleep Apnea
5. Sleepiness

Experts

1. Dauvilliers, Yves: 62 articles (02/2022 - 01/2004)
2. Kanbayashi, Takashi: 37 articles (10/2020 - 07/2002)
3. Mignot, Emmanuel: 24 articles (01/2021 - 10/2002)
4. Plazzi, Giuseppe: 23 articles (01/2022 - 03/2007)
5. Jaussent, Isabelle: 21 articles (02/2022 - 08/2011)
6. Nishino, Seiji: 21 articles (05/2016 - 10/2002)
7. Mayer, Geert: 16 articles (01/2022 - 11/2005)
8. Barateau, Lucie: 15 articles (02/2022 - 01/2015)
9. Black, Jed: 15 articles (01/2022 - 10/2002)
10. Pizza, Fabio: 15 articles (01/2022 - 11/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Disorders of Excessive Somnolence:
1. Modafinil (Provigil)FDA Link
2. Sodium Oxybate (gamma Hydroxybutyrate)FDA Link
3. pitolisantIBA
4. MelatoninIBA
5. OrexinsIBA
6. Oxygen (Dioxygen)IBA
7. Methylphenidate (Ritalin)FDA LinkGeneric
8. N-(4-aminophenethyl)spiroperidol (NAPS)IBA
9. Antidepressive Agents (Antidepressants)IBA
10. Levodopa (L Dopa)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Continuous Positive Airway Pressure
3. Aftercare (After-Treatment)
12/01/1995 - "Excessive daytime sleepiness disappeared and sleep quality improved after treatment in most cases. "
12/01/2017 - "After treatment, nonAR and AR groups improved in daytime sleepiness (11.53 ± 4.60 vs. 7.53 ± 2.87, p = 0.000 and 13.76 ± 4.93 vs. 7.53 ± 4.41, p = 0.001) respectively and increased nasal neutrophil (0.16 ± 0.39 vs. 5.78 ± 9.43, p = 0.001 and 14.42 ± 31.94 vs. 79.47 ± 202.08, p = 0.035). "
08/01/1986 - "In addition to the improvement in respiration during sleep, SSI decreased from a mean of 3.73 +/- 0.49 after the control night to 1.64 +/- 0.24 after treatment, reflecting an improvement in daytime hypersomnolence. "
02/01/2022 - "Two-hundred twenty-six (166 drug-free and 60 treated) patients with IH (cross-sectional sample) completed the 14-item IHSS to quantify the severity of the 3 major IH symptoms (excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia) and consequences; 77 untreated patients were evaluated again after treatment (longitudinal sample). "
12/01/2017 - "Thirty-four consecutive CPAP treatment-adherent patients with OSA (17 AR and 17 nonAR) were evaluated before and 2 months after treatment, by means of clinical (otorhinolaryngological symptoms, daytime sleepiness, overall and rhinoconjunctivitis-specific quality of life), anatomical (otorhinolaryngological examination), functional (auditory function, tubal function, nasal airflow, and mucociliary clearance), and biological variables (nasal cytology). "
4. Nasal Surgical Procedures
5. Tracheostomy